ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE

被引：0
|
作者：
Osterman, Mark T.
Gordon, Ilyssa O.
Davis, Elisabeth M.
Ciorba, Matthew A.
Glover, Sarah C.
Abraham, Bincy P.
Khan, Freeha
Shen, Bo
Yee, Eric
Allard, Felicia
Liu, Julia J.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
D O I：
10.1053/j.gastro.2019.01.148
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P087
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [21] Cannabis can induce a clinical response in patients with Crohn's disease
    Attwood, Claire
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (06) : 602 - 602
  • [22] Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease
    Hageman, I.
    Joustra, V.
    Yim, A. Li
    Davids, M.
    Henneman, P.
    Hakvoort, T.
    Probert, F.
    Satsangi, J.
    D'Haens, G.
    De Jonge, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I603 - I604
  • [23] Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease
    Hageman, I.
    Joustra, V.
    Li Yim, A.
    Davids, M.
    Henneman, P.
    Hakvoort, T.
    Probert, F.
    Satsangi, J.
    D'Haens, G.
    De Jonge, W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I603 - I604
  • [24] Influence of Crohn's Disease-Related Genetic Defects in Innate Immune Function on Ileal-Associated Microbiome
    Zhang, Yuanhao
    Li, Ellen
    Gathungu, Grace
    Sheikh, Shehzad
    Sartor, R. Balfour
    Davidson, Nicholas O.
    Ciorba, Matthew A.
    Xavier, Ramnik
    Zhu, Wei
    Robertson, Charles E.
    Frank, Daniel N.
    GASTROENTEROLOGY, 2016, 150 (04) : S429 - S429
  • [25] PREDICTING RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE - A SINGLE CENTRE EXPERIENCE
    Kane, Claire
    Porter, Ross J.
    Thomson, John
    Smith, Malcolm
    Basavaraju, Umesh
    Bain, Gillian H.
    McLean, Mairi H.
    GUT, 2019, 68 : A86 - A86
  • [26] Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice
    Dulai, Parambir S.
    Peerani, Farhad
    Narula, Neeraj
    Chaudrey, Khadija
    Whitehead, Diana
    Hudesman, David
    Shmidt, Eugenia
    Lukin, Dana J.
    Swaminath, Arun
    Nghia Nguyen
    Meserve, Joseph
    Kane, Sunanda V.
    Singh, Siddharth
    Boland, Brigid S.
    Siegel, Corey A.
    Loftus, Edward V.
    Sandborn, William
    Sands, Bruce E.
    Colombel, Jean-Frederic
    GASTROENTEROLOGY, 2016, 150 (04) : S393 - S393
  • [27] Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn's disease
    Kotze, P. G.
    Ma, C.
    Almutairdi, A.
    Al-Damarki, A.
    Devlin, S.
    Kaplan, G.
    Seow, C.
    Novak, K.
    Lu, C.
    Ferraz, J.
    Stewart, M.
    Buresi, M.
    Mathivanan, M.
    Jijon, H.
    Heatherington, J.
    Martin, M. -L.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S466 - S467
  • [28] Crohn’s disease is caused by a failure of the innate immune response with major abnormalities in macrophage biology
    A W Segal
    Journal of Translational Medicine, 8 (Suppl 1)
  • [29] Antibodies to 12 predict clinical response to fecal diversion in Crohn's disease
    Spivak, Jacob
    Landers, Carol J.
    Vasiliauskas, Eric A.
    Abreu, Maria T.
    Dubinsky, Marla C.
    Papadakis, Konstantinos A.
    Ippoliti, Andrew
    Targan, Stephan R.
    Fleshner, Phillip R.
    INFLAMMATORY BOWEL DISEASES, 2006, 12 (12) : 1122 - 1130
  • [30] Antibodies to 12 predict clinical response to fecal diversion in Crohn's disease
    Spivak, J
    Targan, SR
    Vasiliauskas, EA
    Abreu, MT
    Papadakis, KA
    Landers, CJ
    Fleshner, P
    GASTROENTEROLOGY, 2004, 126 (04) : A69 - A69
12345